Hydroxychloroquine + [additional] = cures and treatments
ANTIPHOSPHOLIPID
Long-term Use of Hydroxychloroquine Reduces Antiphospholipid Antibodies Levels in Patients With Primary Antiphospholipid Syndrome
https://pubmed.ncbi.nlm.nih.gov/27406736/
ASTHMA
Hydroxychloroquine Improves Airflow and Lowers Circulating IgE Levels in Subjects With Moderate Symptomatic Asthma
B L Charous et al. J Allergy Clin Immunol. 1998 Aug.
https://pubmed.ncbi.nlm.nih.gov/9723661/
ASTHMA
Open Study of Hydroxychloroquine in the Treatment of Severe Symptomatic or Corticosteroid-Dependent Asthma
https://pubmed.ncbi.nlm.nih.gov/2195922/
HIV
Hydroxychloroquine Drastically Reduces Immune Activation in HIV-infected, Antiretroviral Therapy-Treated Immunologic Nonresponders
Stefania Piconi et al. Blood. 2011.
https://pubmed.ncbi.nlm.nih.gov/21576701/
INFECTIOUS (MALARIA, HIV, Q FEVER, WHIPPLE DISEASE, FUNGAL INFECTIONS)
RHEUMATOLOGICAL (LUPUS ERYTHEMATOSUS, ANTIPHOSPHOLIPID ANTIBODY SYNDROME, RHEUMATOID ARTHRITIS, SJOGREN’S SYNDROME)
Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases. Indeed, they have anti-inflammatory, immunomodulating, anti-infective, antithrombotic, and metabolic effects.
https://pubmed.ncbi.nlm.nih.gov/29737455/
LUNG CANCER (ONCOLOGY)
Blockade of autophagy by hydroxychloroquine dramatically potentiated KG-135-induced FOXO3a and its downstream (FasL) ligand accompanied by the cleavage of caspase-8. Meanwhile, the decrease of Bcl-2 and survivin, as well as the cleavage of caspase-9, were also drastically enhanced, resulting in massive apoptosis.
https://pubmed.ncbi.nlm.nih.gov/28701864/?from_term=Hydroxychloroquine+drastically&from_pos=6
RHEUMATOID ARTHRITIS (IMMUNE SYSTEM)
Hydroxychloroquine May Be Associated With Reduced Risk of Coronary Artery Diseases in Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study
Yao-Min Hung et al. Int J Clin Pract. 2018 May.
https://pubmed.ncbi.nlm.nih.gov/29691971/
CCP VIRUS (COVID-19)
In addition, the virological clearance at day-6 post-inclusion in HCQ plus azithromycin, HCQ and control arm was 100%, 57.1% and 12.5% respectively (p < 0.001). This data suggests a synergistic effect of azithromycin with HCQ.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102587/
DERMATOLOGY
CARDIOVASCULAR DISORDER
These clinical observations, followed by some well-designed studies, have substantially broadened the horizons for CHQ and analogues over the last few decades. CHQ and analogues have been proven beneficial for many rheumatological, cardiovascular diseases (CVD), and dermatological conditions, and there is a growing body of evidence to support their therapeutic potential in oncology, HIV infection, and chronic kidney disease (CKD).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905642/
ANTI-PHOSPHOLIPID SYNDROME
Long-term Use of Hydroxychloroquine Reduces Antiphospholipid Antibodies Levels in Patients With Primary Antiphospholipid Syndrome
https://pubmed.ncbi.nlm.nih.gov/27406736/
LUPUS
RHEUMATOID ARTHRITIS
SARCOIDOSIS
SJOEGREN SYNDROME
CUTANNEOUS DISORDERS
ANTI-PHOSPHOLIPID SYNDROME
ONCOLOGY
Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology.
https://pubmed.ncbi.nlm.nih.gov/29517495/
PARKINSON’S
Scientists have found that existing anti-malaria drugs could be a potential treatment for Parkinson's disease. Parkinson's disease is a degenerative disorder of the central nervous system that causes a person to lose control of motor movements, such as the …ability to move his or her hands, arms, and legs.
https://www.sciencedaily.com/releases/2015/07/150716091710.htm
MULTIPLE SCLEROSIS
Unexpected Additive Effects of Minocycline and Hydroxychloroquine in Models of Multiple Sclerosis: Prospective Combination Treatment for Progressive Disease?
https://pubmed.ncbi.nlm.nih.gov/28857721/
LYME DISEASE
Before the Lyme diagnosis was made, intravenous immunoglobulin treatment was performed 8 times with subsequent responses and relapses. Combined antibiotics therapy (doxycycline and hydroxychloroquine) was added simultaneously with the last 8 immunoglobulin therapy sessions. The patient showed complete disappearance of neurologic signs, and no adverse reaction was reported.
https://www.amjmed.com/article/S0002-9343(17)30103-1/pdf